ARWR as reported
Arrowhead Pharmaceuticals, Inc. reported $669M of revenue over the trailing twelve months, +17% on the year before. 10 reported series are charted on this page, each one as filed.
$669M
Revenue, trailing twelve months · to Q3 2026 · +17% against the twelve months before
- Net Income
- −$320M
Net Income · +116% year on year · trailing twelve months to Q3 2026
- Free Cash Flow
- −$75M
Free Cash Flow · +326% year on year · trailing twelve months to Q3 2026
- Op Margin
- −96%
Op Margin · trailing twelve months to Q3 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $669M | +17% | Q3 2026 |
| Net Income | −$320M | +116% | Q3 2026 |
| EPS | −$2.25 | +77% | Q3 2026 |
| Op Margin | −96% | n/a | Q3 2026 |
| Net Margin | −109% | n/a | Q3 2026 |
| ROE | −21% | n/a | Q3 2026 |
| ROA | −4.0% | n/a | Q3 2026 |
| ROIC | −16% | n/a | Q3 2026 |
| Free Cash Flow | −$75M | +326% | Q3 2026 |
| P/E | 126 | n/a | Q2 2020 · 25 quarters behind |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Arrowhead Pharmaceuticals, Inc. (ARWR) - Revenue & ProfitRevenue & ProfitArrowhead Pharmaceuticals, Inc. (ARWR)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com